Novo Nordisk is also pairing the long-acting insulin with its once-weekly GLP-1 agonist semaglutide in the COMBINE trials programme, which is due to complete in 2024, is also working on a glucose ...

South Africa's competition watchdog is investigating drugmakers Novo Nordisk and Sanofi over possible anti-competitive ...

During a hearing, representatives for the Newsom administration said they could not provide a timeline for when ...

Up until a few years ago, Novo Nordisk was mainly known for selling insulin and other diabetes treatments. In 2017, it launched Ozempic, a glucagon-like peptide 1 (GLP-1) receptor agonist for the ...